Italy was studied in detail in a report produced by the Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute). The report surveyed measures for promoting the rational use of medicines in the 27 EU member states.
Italy’s rational use of medicines
Home/Reports
|
Posted 08/04/2011
0
Post your comment
Since 2000, the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) has been operating a ‘National Observatory on the Use of Medicines’ (Osservatorio nazionale sull’impiego dei medicinali, OSMED). OSMED monitors and analyses pharmaceutical consumption, e.g. impact of policy measures and comparison to other countries, on a monthly basis. Additionally, yearly reports on pharmaceutical consumption and expenditure are published.
At regular intervals, AIFA runs information campaigns targeted at the general public, e.g. on rational use of antibiotics and promoting generics.
International non-proprietary name prescribing is indicative for doctors and generic substitution is allowed, but not obligatory, for pharmacists in Italy.
Italy has launched a project to trace all medicines brought on to the Italian market, Progetto Tracciabilità del Farmaco, which implied extensive preparatory work (legal framework, IT tools).
Acknowledgement
This article is published with permission of the Gesundheit Österreich GmbH (GÖG)/Austrian Health Institute.
We gratefully acknowledge the support from Dr Sabine Vogler of Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute) to GaBI Online.
Related articles
The EU and rational use of medicines
Survey on rational use of medicines in 27 EU Members States
The Netherlands and rational use of medicines
France’s rational use of medicines
Rational use of medicines in Denmark
Promoting rational use of medicines in Europe
Germany’s rational use of medicines
Reference
Vogler S, Schmickl B. Rational use of medicines in Europe. Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG). February 2010.
Guidelines
Brazil's ANVISA updates guidance on pharmacokinetic studies for biosimilars
Canada eliminates phase III trial requirement for biosimilar approvals
Policies & Legislation
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Congress pushes biosimilar bills as interchangeability concerns linger
Central America moves toward joint evaluation of biosimilar medicines
Home/Reports Posted 22/07/2026
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment